nicotinamide mononucleotide
nicotinamide mononucleotide is a dietary supplement with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy
Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis
Clinical Trials (7)
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy
Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
All 7 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 7